Research programme: viral proteins - Viron Therapeutics
Alternative Names: Cytokine binding proteins- Viron Therapeutics; VT-214; VT-310; VT-346; VT-362; VT-384Latest Information Update: 16 Jan 2017
Price :
$50 *
At a glance
- Originator Viron Therapeutics
- Class Proteins
- Mechanism of Action Chemokine inhibitors; Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada (Parenteral)
- 18 Mar 2010 Pharmacodynamics data from a preclinical trial in inflammation released by Viron